reports
DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadli...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Argos Therapeutics, Inc. (Nasdaq: ARGS) (“Argos” or the “Company”) securities during the period between February 7, 2014 and February 21, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 15, 2...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Argos Therapeutics, Inc. (Nasdaq: ARGS) (“Argos” or the “Company”) securities during the period between February 7, 2014 and February 21, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 15, 2...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation In...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Argos Therapeutics, Inc. (NASDAQ:ARGS). On February 17, 2017, Momenta announced that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration. The Company’s Abbreviated New Drug Application (ANDA) for its Glatopa 40 mg product candidate is still under regulatory review, with final approval reliant upon the acceptable resolution of the compliance obser...
QuickView: Second-generation dendritic cell therapy
Encouraging Phase II survival data at ASCO for Argos's lead product AGS-003 in mRCC have failed to move the stock from levels close to its 52-week low and below its IPO price in February 2014. While investors clearly remain cautious of dendritic cell transfer therapies, data expected mid-2014 (Phase IIb for AGS-004 in HIV) and at end 2015 (interim Phase III for AGS-003 in mRCC) could provide upside from the current EV of $71m.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.